Table 2 Adverse events and end-of-cycle 1 dose-limiting toxicities

From: A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer

  Dosage by grade  
  2.5 mg Daily ( n =6) 5 mg Daily ( n =11) 10 mg Daily ( n =3) All ( n =20)
Adverse events b 1/2 3/4 1/2 3/4 1/2 3/4 Any grade
Haematologic toxicities
Anaemia 5 0 10 1 3 0 19
Neutropenia 3 1 3 6 1 2 16
Thrombocytopenia 2 0 3 1 2 2 12
Febrile neutropenia 0 0 0 1 0 0 1
Leukopenia 4 1 4 4 2 0 15
Nonhaematologic toxicities
Anorexia 2 0 3 0 1 0 6
Vomiting 0 0 2 0 0 0 1
Stomatitis 2 0 5 0 1 0 8
Diarrhoea 0 0 2 0 1 0 3
Neuropathy 1 0 3 1 2 0 7
Pain 2 0 6 0 2 0 10
AST increased 1 0 4 0 1 0 6
ALT increased 1 0 5 0 0 0 6
Hyperglycemia 6 0 9 0 2 1 18
Hypertriglycemia 3 0 2 0 2 0 7
Itching 0 0 2 0 2 0 4
Pneumonitis 0 0 1 0 0 0 1
Dose-limiting toxicity, cycle 1
Thrombocytopenia 0 0 0 1a 0 1 2
Fever with grade 4 neutropenia 0 0 0 1a 0 0 1
Hyperglycemia 0 0 0 0 0 1 1
  1. Abbreviations: ALT=alanine aminotranferease; AST=aspartate aminotransferase.
  2. aTwo dose-limiting toxicities in the same person.
  3. bA patient with multiple occurrence of an adverse event was counted only once in the adverse event category. A patient with multiple severity ratings for an adverse event was only included under the maximum rating.